Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2017

01-01-2017 | Melanomas

Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma?

Authors: Kathryn E. Engelhardt, MD, Jeffrey D. Wayne, MD, Karl Y. Bilimoria, MD, MS

Published in: Annals of Surgical Oncology | Issue 1/2017

Login to get access

Excerpt

Patients with sentinel lymph node (SLN)-positive stage III melanoma have heterogeneous outcomes ranging from 23 to 87 %.1 Due to this variability, it is challenging to provide prognostic information to patients, stratify patients appropriately for clinical trials, and make decisions regarding adjuvant therapy. Thus, there would be value in identifying a gene signature that would allow discrimination of patients with stage III melanoma into high- and low-risk groups. …
Literature
1.
Balch CM, Gershenwald JE, Soong S-J, et al. Multivariate analysis of prognostic factors among 2313 patients with stage iii melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010;28(14):2452–59.CrossRefPubMedPubMedCentral
2.
Hao H, Xiao D, Pan J, et al. Sentinel lymph node genes to predict prognosis in node-positive melanoma patients. Ann Surg Oncol. 2016.
3.
McMasters KM, Egger ME, Edwards MJ, et al. Final results of the Sunbelt Melanoma Trial: a multi-institutional prospective randomized phase III study evaluating the role of adjuvant high-dose interferon alfa-2b and completion lymph node dissection for patients staged by sentinel lymph node biopsy. J Clin Oncol. 2016;34(10):1079–86.CrossRefPubMed
4.
Melanoma of the skin. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual. 7th ed. Chicago, IL: Springer; 2010. pp. 325–44.
5.
Romano E, Scordo M, Dusza SW, Coit DG, Chapman PB. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. J Clin Oncol. 2010;28(18):3042–47.CrossRefPubMedPubMedCentral
6.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599–09.CrossRefPubMedPubMedCentral
7.
8.
9.
van Akkooi ACJ, Atkins MB, Agarwala SS, Lorigan P. Surgical management and adjuvant therapy for high-risk and metastatic melanoma. Am Soc Clin Oncol Educ Book. 2016;2016(35):e505–e514.CrossRef
10.
Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. J Am Acad Dermatol. 2015;72(5):780–85.CrossRefPubMed
11.
Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. Am Assoc Cancer Res. 2015;21(1):175–83.
12.
Lawson DH, Cook RW, Johnson C, et al. Continued evaluation of a 31-gene expression profile test (GEP) for prediction of distant metastasis (DM) in cutaneous melanoma (CM) [abstract no. 9066]. J Clin Oncol. 2015;33(15 Suppl):9066.
13.
Lawson DH, Russell M, Wilkinson J, et al. Gene expression profile of primary cutaneous melanomas to distinguish between low and high risk of metastasis [abstract no. 9022]. J Clin Oncol. 2013;31(15 Suppl):9022.
14.
Dhillon N, Rogers AR, Delman KA, et al. Gene expression profile signature (DecisionDx-Melanoma) to predict visceral metastatic risk in patients with stage I and stage II cutaneous melanoma. J Clin Oncol. 2012;30(15 Suppl):8543.
Metadata
Title
Editorial: Should We Abandon TNM Staging in Favor of Gene Profiles in Node-Positive Melanoma?
Authors
Kathryn E. Engelhardt, MD
Jeffrey D. Wayne, MD
Karl Y. Bilimoria, MD, MS
Publication date
01-01-2017
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 1/2017
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-016-5576-6

Other articles of this Issue 1/2017

Annals of Surgical Oncology 1/2017 Go to the issue

Bone and Soft Tissue Sarcomas

Tailoring Surgical Therapy for Extremity Soft Tissue Sarcoma

Bone and Soft Tissue Sarcomas

Results of Resection for Recurrent or Residual Retroperitoneal Sarcoma After Failed Primary Treatment

Palliative Care

A Singular Hope: How the Discussion Around Cancer Surgery Sometimes Fails

Breast Oncology

Breast Cancer in Male Adolescents and Young Adults

Breast Oncology

Impact of an In-visit Decision Aid on Patient Knowledge about Contralateral Prophylactic Mastectomy: A Pilot Study

Colorectal Cancer

“Adjuvant” Hyperthermic Intraperitoneal Chemotherapy: A Call to Action